Knight TherapeuticsTSX:GUD +1.30%73 EBITDA Margin % is 22.24% as of Mar. 2026, which is 45% above its 10-year median of 15.37. GuruFocus rates TSX:GUD with a GF Score™ of 73/100 and a GF Value™ of C$8.63 (Fairly Valued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Knight Therapeutics ranks better than 58.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Knight Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was C$33.0 Mil. Knight Therapeutics's Revenue for the
three
months ended in Mar. 2026 was C$148.4 Mil. Therefore, Knight Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 22.24%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Knight Therapeutics EBITDA Margin % Related Terms
Knight Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics (TSX:GUD) has a EBITDA Margin % of 22.24% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Knight Therapeutics and its competitors. This is 45% above median its historical median of 15.37. According to the industry distribution chart, Knight Therapeutics ranks #399 out of 955 companies in the Drug Manufacturers industry, placing it in the top 41.8%.
Is Knight Therapeutics' EBITDA Margin % too high?
Knight Therapeutics' current EBITDA Margin % of 22.24% is 45% above median its 10-year median of 15.37. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Knight Therapeutics' value of 22.24% is 79.5% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #399 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #399 out of 955 companies for EBITDA Margin %. This puts Knight Therapeutics in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Knight Therapeutics' value of 22.24% is 79.5% above this benchmark. While the company's 10-year median is 15.37 vs. the industry median of 12.39, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current EBITDA Margin % of 22.24% is 79.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current EBITDA Margin % is 22.24%, which is 45% above median its own 10-year median of 15.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Fairly Valued. The stock's GF Value™ is C$8.63, compared to a current price of C$9.35 — trading 8.3% above its estimated fair value. The current EBITDA Margin % is 22.24%, which is 45% above median its 10-year median of 15.37 and 79.5% above the Drug Manufacturers industry median of 12.39. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current EBITDA Margin % is 22.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of C$9.35 is trading 8.3% above its estimated GF Value™ of C$8.63.
GuruFocus considers Knight Therapeutics to be Fairly Valued.
Key valuation signals for TSX:GUD:
EBITDA Margin %: 22.24% (45% above median its 10-year median of 15.37)
GF Value™: C$8.63 vs. price of C$9.35 (8.3% above fair value)
Industry Position: 79.5% above the Drug Manufacturers median (#399 of 955)
No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for TSX:GUD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:GUD has been successfully added to your 
